Kaposiform Hemangioendothelioma: Therapeutic efficacy for an enigmatic diagnosis

Pediatric Blood and Cancer

Volumn 62, Issue 4, 2015, Pages 551-552

  Blei, Francine ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PROPRANOLOL; RAPAMYCIN; VINCRISTINE; ANTINEOPLASTIC AGENT; STEROID;

ARTICLE; BLOOD CLOTTING DISORDER; CANCER DIAGNOSIS; CONGENITAL BLOOD VESSEL MALFORMATION; DRUG EFFICACY; FOLLOW UP; HEMANGIOENDOTHELIOMA; HUMAN; HYPOFIBRINOGENEMIA; KAPOSIFORM HEMANGIOENDOTHELIOMA; KASABACH MERRITT SYNDROME; PHLEBOTOMY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; KASABACH-MERRITT SYNDROME; MALE; SARCOMA, KAPOSI;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMANGIOENDOTHELIOMA; HUMANS; KASABACH-MERRITT SYNDROME; MALE; SARCOMA, KAPOSI; STEROIDS; VINCRISTINE;

EID: 84923221780     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25365     Document Type: Article

References (12)

1. Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100:1377-1386.
2. Enjolras O, Wassef M, Mazoyer E, Frieden IJ, Rieu PN, Drouet L, Taïeb A, Stalder JF, Escande JP. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr 1997; 130:631-640.
3. Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, Trenor CC III. Kaposiform hemangioendothelioma: Atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 2013; 162:142-147. doi:10.1016/j.jpeds.2012.06.044. Epub 2012 Aug 4.
4. Haisley-Royster C, Enjolras O, Frieden IJ, Garzon M, Lee M, Oranje A, de Laat PC, Madern GC, Gonzalez F, Frangoul H, Le Moine P, Prose NS, Adams DM. Kasabach-Merritt phenomenon: A retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002; 24:459-462. Erratum in J Pediatr Hematol Oncol 2002 Dec;24(9):794.
5. Drolet BA, Trenor CC III, Brandão LR, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, Blei F, David M, Elluru R, Frieden IJ, Friedlander SF, Iacobas I, Jensen JN, King DM, Lee MT, Nelson S, Patel M, Pope E, Powell J, Seefeldt M, Siegel DH, Kelly M, Adams DM. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr 2013; 163:285-291. doi:10.1016/j.jpeds.2013.03.080
6. Shirazi F, Cohen C, Fried L, Arbiser JL. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 2007; 5:233-236.
7. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364:1595-1606.
8. Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57:1018-1024. doi:10.1002/pbc.23124. Epub 2011 Mar 28.
9. Wang Z. Steroid-resistant kaposiform hemangioendothelioma: A retrospective study of 37 patients treated with vincristine and long-term follow-up. Pediatr Blood Cancer 2014;14-0208.
10. Wang Z, Li K, Dong K, Xiao X, Zheng S. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus. J Pediatr Hematol Oncol 2013; 37:72-73.
11. Enjolras O, Mulliken JB, Wassef M, Frieden IJ, Rieu PN, Burrows PE, Salhi A, Léauté-Labreze C, Kozakewich HP. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol 2000; 42:225-235.
12. Kai L, Wang Z, Yao W, Dong K, Xiao X. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. J Cancer Res Clin Oncol 2014; 140:471-476.